What is the appropriate dosing, route, efficacy, safety, and contraindications for using aprepitant as a short‑course anti‑emetic in patients with gastroparesis whose nausea or vomiting is not adequately controlled by standard agents such as metoclopramide, ondansetron, or prochlorperazine?

Aprepitant for Refractory Gastroparesis

Aprepitant at 80 mg daily can be considered as a second-line antiemetic option for gastroparesis patients with refractory nausea and vomiting uncontrolled by metoclopramide, ondansetron, or prochlorperazine, though evidence shows it may benefit only about one-third of patients and cost considerations are significant. 1

Mechanism and Rationale

Aprepitant is a neurokinin-1 (NK-1) receptor antagonist that blocks substance P in critical areas involved in nausea and vomiting, including the nucleus tractus solitarius and area postrema 1. Unlike prokinetic agents, aprepitant does not accelerate gastric emptying—its benefit is purely antiemetic through central nervous system pathways 2.

Dosing for Gastroparesis

The recommended dose for gastroparesis is 80 mg orally once daily 1. This differs from the chemotherapy-induced nausea regimen (125 mg day 1, then 80 mg days 2-3) 3. The gastroparesis dosing is based on the single RCT in this population that used 125 mg daily, but the guideline-recommended practical dose is 80 mg daily 1.

Efficacy Evidence

The evidence for aprepitant in gastroparesis is limited but shows modest benefit:

• An RCT of 126 gastroparesis patients found that aprepitant 125 mg/day improved nausea and vomiting scores on the Gastroparesis Cardinal Symptom Index (GCSI), though it did not improve visual analog scale assessment of nausea intensity 1

• Approximately one-third of patients with troublesome nausea may benefit from NK-1 receptor antagonists, provided costs are affordable 1

• The improvement occurs regardless of whether gastric emptying is delayed or normal, suggesting the benefit is independent of the underlying motility disorder 1

• A case report demonstrated dramatic symptom improvement within 48 hours at 40 mg daily, with sustained benefit over 2 months 2

Route of Administration

Aprepitant is administered orally only for gastroparesis 1. The capsules can be taken with or without food, as food increases AUC by only 9-20% 4. This oral-only formulation may be problematic in patients with severe vomiting who cannot tolerate oral medications—a key limitation in this population.

Safety Profile

Aprepitant is generally well-tolerated in gastroparesis:

• Most common side effects in the postoperative setting include headache, dizziness, and fatigue 3
• No significant cardiovascular risks like QT prolongation (unlike domperidone or metoclopramide) 1
• No extrapyramidal symptoms (unlike metoclopramide) 1
• The drug was well-tolerated in the gastroparesis RCT with no significant adverse events reported 1

Critical Drug Interactions

Aprepitant is metabolized via CYP3A4 and acts as both a substrate and moderate inhibitor of this enzyme 5, 3. Key interactions include:

• Warfarin: Monitor INR closely for 2 weeks after initiation, particularly at 7-10 days 3
• Hormonal contraceptives: Efficacy may be reduced; use backup contraception during treatment and for 1 month after the last dose 3
• Corticosteroids: When combined with dexamethasone, reduce the corticosteroid dose by 50% due to increased plasma concentrations 5
• Other CYP3A4 substrates: Potential for increased levels of drugs like benzodiazepines, certain chemotherapy agents, and immunosuppressants

Contraindications

Aprepitant is contraindicated with concurrent use of pimozide due to risk of serious or life-threatening reactions 3. There are no other absolute contraindications, though caution is warranted with:

• Severe hepatic impairment (no dose adjustment needed for mild-moderate impairment)
• Patients taking multiple CYP3A4 substrates with narrow therapeutic indices

Position in Treatment Algorithm

Based on the 2022 AGA expert review 1:

1. First-line: Metoclopramide (5-20 mg tid-qid) or 5-HT3 antagonists (ondansetron 4-8 mg bid-tid, granisetron 1 mg bid or transdermal patch)
2. Second-line: Consider aprepitant 80 mg daily if first-line agents fail
3. Alternative second-line options: Phenothiazines (prochlorperazine 5-10 mg qid), antihistamines, or tricyclic antidepressants for symptom modulation

The 2025 AGA clinical practice guideline issued a conditional recommendation AGAINST using aprepitant as first-line therapy for gastroparesis 6, reinforcing its role as a second-line option only.

Cost Considerations

Cost is a major barrier to aprepitant use 1. The medication is significantly more expensive than standard antiemetics. In the case report, the patient discontinued aprepitant after 2 months specifically due to cost, though interestingly maintained some symptom improvement even after discontinuation 2. This cost-benefit analysis should be discussed with patients before initiating therapy.

Clinical Pearls and Pitfalls

• Do not expect improvement in gastric emptying—aprepitant is purely antiemetic and does not address the underlying motility disorder 2
• Consider a trial period of 2-4 weeks to assess response, as benefit may not be immediate in all patients
• The oral formulation limits use in severe vomiting—patients must be able to tolerate oral intake
• Screen for drug interactions before prescribing, particularly warfarin and hormonal contraceptives
• Set realistic expectations: Only about one-third of patients will have meaningful benefit 1
• Consider cost: Discuss financial implications upfront and explore patient assistance programs if available